AnthG82
New member
- Awards
- 0
Found a story below. Any thoughts ?
Shares in a British pharmaceutical company have surged after successful trials for its fast acting gel to combat erectile dysfunction.
Trials with 232 men found the gel had the desired effect with the vast majority - 82 per cent - within ten minutes.
That makes the gel a serious rival to Viagra, which generally takes 30 minutes to work.
As such, the British manufacturer, Futuru Medical, could be line to grab a share of a global market for erectile dysfunction treatments worth $5billion a year.
Shares in the Guildford based company more than doubled on Wednesday after it revealed details of the successful trial of the gel, which is known as MED2002 and branded as Eroxon.
The firm said: ‘The speed of onset of action of MED2002 was rapid, partly reflecting the method of application with the gel being applied directly to the penis.
‘82per cent of patients with mild erectile dysfunction(ED) had an onset of action within 10 minutes and in 54per cent of mild ED patients onset was within 5 minutes.
‘This rapid onset of action means that MED2002 has the potential of being the world’s fastest-acting treatment for ED.’
It said: ‘No major safety concerns were identified. No serious adverse events or serious adverse reactions were recorded and there were no drop-outs from the study owing to side-effect issues.’
As a result, it said the gel could be sold as an over the counter product as well as being offered through prescription.
Shares in a British pharmaceutical company have surged after successful trials for its fast acting gel to combat erectile dysfunction.
Trials with 232 men found the gel had the desired effect with the vast majority - 82 per cent - within ten minutes.
That makes the gel a serious rival to Viagra, which generally takes 30 minutes to work.
As such, the British manufacturer, Futuru Medical, could be line to grab a share of a global market for erectile dysfunction treatments worth $5billion a year.
Shares in the Guildford based company more than doubled on Wednesday after it revealed details of the successful trial of the gel, which is known as MED2002 and branded as Eroxon.
The firm said: ‘The speed of onset of action of MED2002 was rapid, partly reflecting the method of application with the gel being applied directly to the penis.
‘82per cent of patients with mild erectile dysfunction(ED) had an onset of action within 10 minutes and in 54per cent of mild ED patients onset was within 5 minutes.
‘This rapid onset of action means that MED2002 has the potential of being the world’s fastest-acting treatment for ED.’
It said: ‘No major safety concerns were identified. No serious adverse events or serious adverse reactions were recorded and there were no drop-outs from the study owing to side-effect issues.’
As a result, it said the gel could be sold as an over the counter product as well as being offered through prescription.
